Literature DB >> 17393240

Impact of continuous positive airway pressure therapy on blood pressure in patients with obstructive sleep apnea hypopnea: a meta-analysis of randomized controlled trials.

M Alajmi1, A T Mulgrew, J Fox, W Davidson, M Schulzer, E Mak, C F Ryan, J Fleetham, P Choi, N T Ayas.   

Abstract

Patients with untreated obstructive sleep apnea hypopnea (OSAH) are predisposed to developing hypertension, and therapy with continuous positive airway pressure (CPAP) may reduce blood pressure (BP). The purpose of this study was to assess the impact of CPAP therapy on BP in patients with OSAH. We performed a comprehensive literature search up to July 2006 [Medline, PubMed, EMBASE, Cochrane Database of Systematic Reviews (CDSR), Cochrane controlled trials register (CCTR), and Database of Abstract and Reviews of Effect (DARE)] to identify clinical studies and systemic reviews that examined the impact of CPAP on BP. Studies were included if they (1) were randomized controlled trials with an appropriate control group, (2) included systolic and diastolic BP measurements before and after CPAP/control in patients with OSAH, and (3) contained adequate data to perform a meta-analysis. To calculate pooled results, studies were weighted by inverse variances, with either a fixed or a random effects model used depending on the presence of heterogeneity (assessed with Q test). Ten studies met our inclusion criteria (587 patients): three studies were crossover (149 patients) and seven were parallel in design. Seven studies (421 patients) used 24-h ambulatory BP and three used one-time measurements. Two studies were of patients with heart failure (41 patients). Overall, the effects of CPAP were modest and not statistically significant; CPAP (compared to control) reduced systolic BP (SBP) by 1.38 mmHg (95% CI: 3.6 to -0.88, p = 0.23) and diastolic BP (DBP) by 1.52 mmHg (CI: 3.1 to -0.07; p = 0.06). Six of the trials studied more severe OSAH (mean AHI > 30/h, 313 patients); in these six trials, CPAP reduced SBP by 3.03 mmHg (CI 6.7 to -0.61; p = 0.10) and DBP by 2.03 mmHg (CI: 4.1 to -0.002; p = 0.05). There was a trend for SBP reduction to be associated with CPAP compliance. In unselected patients with sleep apnea, CPAP has very modest effects on BP. However, we cannot exclude the possibility that certain subgroups of patients may have more robust responses-this may include patients with more severe OSAH or difficult-to-control hypertension. Future randomized controlled trials in this area should potentially concentrate on these subgroups of patients.

Entities:  

Mesh:

Year:  2007        PMID: 17393240     DOI: 10.1007/s00408-006-0117-x

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  31 in total

1.  Effects of continuous positive airway pressure versus supplemental oxygen on 24-hour ambulatory blood pressure.

Authors:  Daniel Norman; José S Loredo; Richard A Nelesen; Sonia Ancoli-Israel; Paul J Mills; Michael G Ziegler; Joel E Dimsdale
Journal:  Hypertension       Date:  2006-04-03       Impact factor: 10.190

2.  Inhibition of awake sympathetic nerve activity of heart failure patients with obstructive sleep apnea by nocturnal continuous positive airway pressure.

Authors:  Kengo Usui; T Douglas Bradley; Jonas Spaak; Clodagh M Ryan; Toshihiko Kubo; Yasuyuki Kaneko; John S Floras
Journal:  J Am Coll Cardiol       Date:  2005-06-21       Impact factor: 24.094

3.  Previously unrecognized obstructive sleep apnea in Chinese subjects with essential hypertension.

Authors:  M Ip; K F Chung; K N Chan; S P Lam; K Lee
Journal:  Lung       Date:  1999       Impact factor: 2.584

4.  Continuous positive airway pressure therapy for treating sleepiness in a diverse population with obstructive sleep apnea: results of a meta-analysis.

Authors:  Sanjay R Patel; David P White; Atul Malhotra; Michael L Stanchina; Najib T Ayas
Journal:  Arch Intern Med       Date:  2003-03-10

5.  Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study.

Authors:  Jose M Marin; Santiago J Carrizo; Eugenio Vicente; Alvar G N Agusti
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

6.  Effectiveness of continuous positive airway pressure in mild sleep apnea-hypopnea syndrome.

Authors:  C Monasterio; S Vidal; J Duran; M Ferrer; C Carmona; F Barbé; M Mayos; N Gonzalez-Mangado; M Juncadella; A Navarro; R Barreira; F Capote; L R Mayoralas; G Peces-Barba; J Alonso; J M Montserrat
Journal:  Am J Respir Crit Care Med       Date:  2001-09-15       Impact factor: 21.405

7.  Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in the sleep apnea-hypopnea syndrome.

Authors:  J F Faccenda; T W Mackay; N A Boon; N J Douglas
Journal:  Am J Respir Crit Care Med       Date:  2001-02       Impact factor: 21.405

8.  A randomized controlled trial of continuous positive airway pressure in mild obstructive sleep apnea.

Authors:  Maree Barnes; Danielle Houston; Christopher J Worsnop; Alister M Neill; Ivanka J Mykytyn; Amanda Kay; John Trinder; Nicholas A Saunders; R Douglas McEvoy; Robert J Pierce
Journal:  Am J Respir Crit Care Med       Date:  2002-03-15       Impact factor: 21.405

9.  Efficacy of positive airway pressure and oral appliance in mild to moderate obstructive sleep apnea.

Authors:  Maree Barnes; R Douglas McEvoy; Siobhan Banks; Natalie Tarquinio; Christopher G Murray; Norman Vowles; Robert J Pierce
Journal:  Am J Respir Crit Care Med       Date:  2004-06-16       Impact factor: 21.405

10.  Evidence for lipid peroxidation in obstructive sleep apnea.

Authors:  Lena Lavie; Alona Vishnevsky; Peretz Lavie
Journal:  Sleep       Date:  2004-02-01       Impact factor: 5.849

View more
  72 in total

1.  Sleep and hypertension.

Authors:  David A Calhoun; Susan M Harding
Journal:  Chest       Date:  2010-08       Impact factor: 9.410

Review 2.  Obstructive sleep apnea and hypertension.

Authors:  David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2010-06       Impact factor: 5.369

3.  To sleep, perchance to dip: obstructive sleep apnea, blood pressure, and cardiovascular disease.

Authors:  Nabil M Al Lawati; Najib T Ayas
Journal:  Sleep       Date:  2008-06       Impact factor: 5.849

4.  Sleep-disordered breathing and stroke: therapeutic approaches.

Authors:  Melissa C Lipford; John G Park; Kannan Ramar
Journal:  Curr Neurol Neurosci Rep       Date:  2014-02       Impact factor: 5.081

5.  The impact of CPAP on cardiovascular biomarkers in minimally symptomatic patients with obstructive sleep apnea: a pilot feasibility randomized crossover trial.

Authors:  Vikram R Comondore; Rupi Cheema; Joel Fox; Arsalan Butt; G B John Mancini; John A Fleetham; C Frank Ryan; Sammy Chan; Najib T Ayas
Journal:  Lung       Date:  2008-09-16       Impact factor: 2.584

Review 6.  Obstructive sleep apnea and hypertension: mechanisms, evaluation, and management.

Authors:  John M Dopp; Kevin J Reichmuth; Barbara J Morgan
Journal:  Curr Hypertens Rep       Date:  2007-12       Impact factor: 5.369

7.  Obstructive sleep apnea and heart failure.

Authors:  Andrew D Calvin; Felipe N Albuquerque; Taro Adachi; Virend K Somers
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-12

Review 8.  Ethical issues in the conduct of clinical trials in obstructive sleep apnea.

Authors:  Devin L Brown; Craig S Anderson; Ronald D Chervin; Clete A Kushida; Daniel S Lewin; Beth A Malow; Susan Redline; Edward B Goldman
Journal:  J Clin Sleep Med       Date:  2011-02-15       Impact factor: 4.062

Review 9.  Hypoxia-inducible factors and obstructive sleep apnea.

Authors:  Nanduri R Prabhakar; Ying-Jie Peng; Jayasri Nanduri
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

10.  Effects of positive airway pressure treatment on clinical measures of hypertension and type 2 diabetes.

Authors:  Bharati Prasad; David W Carley; Jerry A Krishnan; Terri E Weaver; Frances M Weaver
Journal:  J Clin Sleep Med       Date:  2012-10-15       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.